BR112014007963A2 - aminotiazoles substituídos como inibidores de cãncer, incluindo carcinoma hepatocelular, e como inibidores da replicação do vírus da hepatite - Google Patents
aminotiazoles substituídos como inibidores de cãncer, incluindo carcinoma hepatocelular, e como inibidores da replicação do vírus da hepatiteInfo
- Publication number
- BR112014007963A2 BR112014007963A2 BR112014007963A BR112014007963A BR112014007963A2 BR 112014007963 A2 BR112014007963 A2 BR 112014007963A2 BR 112014007963 A BR112014007963 A BR 112014007963A BR 112014007963 A BR112014007963 A BR 112014007963A BR 112014007963 A2 BR112014007963 A2 BR 112014007963A2
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitors
- hepatocellular carcinoma
- virus replication
- hepatitis virus
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161542907P | 2011-10-04 | 2011-10-04 | |
| PCT/US2012/058674 WO2013052613A1 (en) | 2011-10-04 | 2012-10-04 | Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014007963A2 true BR112014007963A2 (pt) | 2013-04-11 |
Family
ID=48044139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014007963A BR112014007963A2 (pt) | 2011-10-04 | 2012-10-04 | aminotiazoles substituídos como inibidores de cãncer, incluindo carcinoma hepatocelular, e como inibidores da replicação do vírus da hepatite |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20140249154A1 (pt) |
| EP (1) | EP2763674A4 (pt) |
| JP (2) | JP6240078B2 (pt) |
| KR (1) | KR20140071472A (pt) |
| CN (1) | CN103957908A (pt) |
| AU (1) | AU2012318670B2 (pt) |
| BR (1) | BR112014007963A2 (pt) |
| CA (1) | CA2850779A1 (pt) |
| HK (1) | HK1200361A1 (pt) |
| IL (1) | IL231923A0 (pt) |
| SG (1) | SG11201401207XA (pt) |
| WO (1) | WO2013052613A1 (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9582896B2 (en) * | 2011-09-02 | 2017-02-28 | Qualcomm Incorporated | Line tracking with automatic model initialization by graph matching and cycle detection |
| NZ707366A (en) | 2012-11-07 | 2018-11-30 | Karus Therapeutics Ltd | Novel histone deacetylase inhibitors and their use in therapy |
| US20160031874A1 (en) * | 2013-03-13 | 2016-02-04 | The Broad Institute, Inc. | Substituted aminothiazoles for the treatment of tuberculosis |
| AU2014264370B2 (en) | 2013-05-10 | 2017-12-14 | Karus Therapeutics Ltd | Novel histone deacetylase inhibitors |
| WO2016046759A2 (en) | 2014-09-22 | 2016-03-31 | Fratagene Therapeutics Ltd. | Compositions and methods for treating friedreich's ataxia |
| US10442779B2 (en) | 2014-09-22 | 2019-10-15 | Fratagene Therapeutics S.R.L. | Compositions and methods for treating Friedreich's ataxia |
| GB201419264D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| GB201419228D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| US20180221406A1 (en) * | 2015-04-29 | 2018-08-09 | Foresight Biotherapeutics, Inc. | Therapeutic combinations of antiviral and anti-inflammatory therapies |
| CN105524056A (zh) * | 2016-01-05 | 2016-04-27 | 中山大学肿瘤防治中心 | 一种氨基噻唑化合物及其制备方法和应用 |
| WO2018013508A1 (en) * | 2016-07-11 | 2018-01-18 | Baruch S. Blumberg Institute | Substituted aminothiazoles |
| CN110996955A (zh) * | 2017-06-22 | 2020-04-10 | 细胞基因公司 | 以乙型肝炎病毒感染为特征的肝细胞癌的治疗 |
| US10426775B2 (en) | 2017-09-11 | 2019-10-01 | Fratagene Therapeutics Srl | Methods for treating Friedreich's ataxia with etravirine |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1261607B1 (en) * | 2000-03-01 | 2008-11-12 | Janssen Pharmaceutica N.V. | 2,4-disubstituted thiazolyl derivatives |
| CN100496493C (zh) * | 2001-08-13 | 2009-06-10 | 詹森药业有限公司 | 2-氨基-4,5-三取代噻唑基衍生物 |
| CA2561267A1 (en) * | 2004-03-30 | 2005-10-20 | Merck & Co., Inc. | 2-aminothiazole compounds useful as aspartyl protease inhibitors |
| CA2562242A1 (en) * | 2004-04-13 | 2005-10-27 | Icagen, Inc. | Polycylic thiazoles as potassium ion channel modulators |
| UA92746C2 (en) | 2005-05-09 | 2010-12-10 | Акилайон Фармасьютикалз, Инк. | Thiazole compounds and methods of use |
| JP2009529059A (ja) * | 2006-03-08 | 2009-08-13 | アキリオン ファーマシューティカルズ，インコーポレーテッド | 抗ｃ型肝炎ウイルス活性を有する置換アミノチアゾール誘導体 |
| WO2008083098A1 (en) * | 2006-12-27 | 2008-07-10 | The Johns Hopkins University | Agents for reversing epigenetic silencing of genes |
| US20110105436A1 (en) * | 2008-03-10 | 2011-05-05 | Auckland Uniservices Limited | Heteroaryl compounds, compositions, and methods of use in cancer treatment |
| CA2793276A1 (en) * | 2009-03-27 | 2010-09-30 | Zacharon Pharmaceuticals, Inc. | Ganglioside biosynthesis modulators |
-
2012
- 2012-10-04 JP JP2014534680A patent/JP6240078B2/ja not_active Expired - Fee Related
- 2012-10-04 AU AU2012318670A patent/AU2012318670B2/en not_active Ceased
- 2012-10-04 WO PCT/US2012/058674 patent/WO2013052613A1/en active Application Filing
- 2012-10-04 BR BR112014007963A patent/BR112014007963A2/pt not_active IP Right Cessation
- 2012-10-04 CA CA2850779A patent/CA2850779A1/en not_active Abandoned
- 2012-10-04 US US14/349,014 patent/US20140249154A1/en not_active Abandoned
- 2012-10-04 CN CN201280059490.1A patent/CN103957908A/zh active Pending
- 2012-10-04 EP EP12838333.8A patent/EP2763674A4/en not_active Withdrawn
- 2012-10-04 SG SG11201401207XA patent/SG11201401207XA/en unknown
- 2012-10-04 KR KR1020147011691A patent/KR20140071472A/ko not_active Application Discontinuation
-
2014
- 2014-04-03 IL IL231923A patent/IL231923A0/en unknown
-
2015
- 2015-01-30 HK HK15101053.5A patent/HK1200361A1/xx unknown
-
2016
- 2016-09-07 US US15/258,393 patent/US10087173B2/en not_active Expired - Fee Related
-
2017
- 2017-04-13 JP JP2017079817A patent/JP2017149753A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017149753A (ja) | 2017-08-31 |
| US10087173B2 (en) | 2018-10-02 |
| CN103957908A (zh) | 2014-07-30 |
| US20140249154A1 (en) | 2014-09-04 |
| AU2012318670A1 (en) | 2014-05-22 |
| US20170066758A1 (en) | 2017-03-09 |
| AU2012318670B2 (en) | 2017-09-07 |
| WO2013052613A1 (en) | 2013-04-11 |
| IL231923A0 (en) | 2014-05-28 |
| CA2850779A1 (en) | 2013-04-11 |
| JP6240078B2 (ja) | 2017-11-29 |
| EP2763674A4 (en) | 2015-04-29 |
| SG11201401207XA (en) | 2014-05-29 |
| JP2014528450A (ja) | 2014-10-27 |
| EP2763674A1 (en) | 2014-08-13 |
| KR20140071472A (ko) | 2014-06-11 |
| HK1200361A1 (en) | 2015-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014007963A2 (pt) | aminotiazoles substituídos como inibidores de cãncer, incluindo carcinoma hepatocelular, e como inibidores da replicação do vírus da hepatite | |
| LTC2410844I2 (lt) | Hepatito C viruso replikacijos inhibitoriai | |
| HRP20190578T1 (hr) | Inhibitori virusa hepatitisa c | |
| CY2015012I2 (el) | Αναστολεις του ιου της ηπατιτιδας c | |
| BRPI1014084A2 (pt) | inibidores do vírus da hepatite c | |
| BRPI1013393A2 (pt) | inibidores do vírus da hepatite c | |
| BRPI1007836A2 (pt) | Inibidores do vírus c da hepatite | |
| BRPI1008846A2 (pt) | inibidores do vírus da hepatite c | |
| SMT201700029B (it) | Inibitori del virus dell'epatite c | |
| DK2903967T3 (da) | Acylaminopyrimidinderivater til behandling af virusinfektioner og yderligere sygdomme | |
| CO6890100A2 (es) | Tratamientos de combinación para hepatitis c | |
| BR112013004520A2 (pt) | inibidores potentes e seletivos do virus da hepatite c | |
| ZA201306720B (en) | Hepatitis c virus inhibitors | |
| CO6940424A2 (es) | Inhibidores del virus de la hepatitis c | |
| CO6821952A2 (es) | Inihibidores del virus de la hepatitis c | |
| HK1212332A1 (en) | Hepatitis c virus inhibitors | |
| BR112014003556A2 (pt) | método de tratamento de vírus, e, composição farmacêutica | |
| BR112013025021A2 (pt) | alisporivir para tratar infecções por vírus de hepatite c. | |
| TH105924B (th) | สารยับยั้งไวรัสตับอักเสบ c |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: PHILADELPHIA HEALTH AND EDUCATION CORPORATION D/B/ |
|
| B25D | Requested change of name of applicant approved |
Owner name: PHILADELPHIA HEALTH AND EDUCATION CORPORATION D/B/ |
|
| B25D | Requested change of name of applicant approved |
Owner name: BARUCH S. BLUMBERG INSTITUTE (US) ; DREXEL UNIVERS |
|
| B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: BARUCH S. BLUMBERG INSTITUTE (US) ; DREXEL UNIVERSITY (US) Free format text: ANULADA A PUBLICACAO CODIGO 25.4 NA RPI NO 2478 DE 03/07/2018 POR TER SIDO INDEVIDA. Owner name: BARUCH S. BLUMBERG INSTITUTE (US) ; DREXEL UNIVERS Free format text: ANULADA A PUBLICACAO CODIGO 25.4 NA RPI NO 2478 DE 03/07/2018 POR TER SIDO INDEVIDA. |
|
| B25D | Requested change of name of applicant approved |
Owner name: BARUCH S. BLUMBERG INSTITUTE (US) ; DREXEL UNIVERSITY (US) Owner name: BARUCH S. BLUMBERG INSTITUTE (US) ; DREXEL UNIVERS |
|
| B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: BARUCH S. BLUMBERG INSTITUTE (US) ; DREXEL UNIVERSITY (US) Free format text: ANULADA A PUBLICACAO CODIGO 25.4 NA RPI NO 2490 DE 25/09/2018 POR TER SIDO INDEVIDA. Owner name: BARUCH S. BLUMBERG INSTITUTE (US) ; DREXEL UNIVERS Free format text: ANULADA A PUBLICACAO CODIGO 25.4 NA RPI NO 2490 DE 25/09/2018 POR TER SIDO INDEVIDA. |
|
| B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: BARUCH S. BLUMBERG INSTITUTE (US) ; DREXEL UNIVERSITY (US) Free format text: ANULADA A PUBLICACAO CODIGO 25.4 NA RPI NO 2476 DE 19/06/2018 POR TER SIDO INDEVIDA. Owner name: BARUCH S. BLUMBERG INSTITUTE (US) ; DREXEL UNIVERS Free format text: ANULADA A PUBLICACAO CODIGO 25.4 NA RPI NO 2476 DE 19/06/2018 POR TER SIDO INDEVIDA. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A,6A E 7A ANUIDADES |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2580 DE 2020-06-16 |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |